Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miriplatin
- Development stage
- Unknown
- Lead developer
- Sumitomo Pharma
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intra-arterial
01
Overview
Miriplatin is a novel lipophilic platinum complex developed for the treatment of hepatocellular carcinoma (HCC). It is specifically designed for use in transcatheter arterial chemoembolization (TACE), where it is suspended in lipiodol and administered intra-arterially to target liver tumors. The drug acts as a DNA cross-linking agent and DNA synthesis inhibitor, similar to other platinum-based chemotherapeutics. Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in 2009 and marketed under the brand name Miripla by Sumitomo Pharma. Its high lipid solubility allows for selective retention within hepatic tumors when delivered via TACE, maximizing local antitumor effects while minimizing systemic toxicity[1][3][4][9].
- Brand names
- Miripla
- Other names
- miriplatin hydrate
02
Targets
DNA
Beyond the preview
Go deeper on miriplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miriplatin.